InMed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INM) $0.45 +0.01 (+2.27%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.41▼$0.4550-Day Range$0.37▼$0.9952-Week Range$0.29▼$3.03Volume178,540 shsAverage Volume263,972 shsMarket Capitalization$2.37 millionP/E RatioN/ADividend YieldN/APrice Target$45.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media InMed Pharmaceuticals MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside9,900.0% Upside$45.00 Price TargetShort InterestHealthy0.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.70 out of 5 stars 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $45.00, InMed Pharmaceuticals has a forecasted upside of 9,900.0% from its current price of $0.45.Amount of Analyst CoverageInMed Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.09% of the outstanding shares of InMed Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently decreased by 74.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInMed Pharmaceuticals does not currently pay a dividend.Dividend GrowthInMed Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INM. Previous Next 3.0 News and Social Media Coverage News SentimentInMed Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InMed Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.39% of the stock of InMed Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 0.47% of the stock of InMed Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioInMed Pharmaceuticals has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About InMed Pharmaceuticals Stock (NASDAQ:INM)InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Read More INM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INM Stock News HeadlinesNovember 14, 2023 | finance.yahoo.comInMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business UpdateNovember 8, 2023 | msn.comInMed Pharmaceuticals files to sell 12.57M shares for holdersDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 8, 2023 | morningstar.comInMed Pharmaceuticals Inc INMNovember 2, 2023 | finance.yahoo.comInMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023October 27, 2023 | finance.yahoo.comInMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq RulesOctober 25, 2023 | investorplace.comWhy Is InMed Pharmaceuticals (INM) Stock Down 25% Today?October 24, 2023 | msn.comInMed Pharmaceuticals to raise $5.2M via private placementDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 24, 2023 | finance.yahoo.comInMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq RulesOctober 24, 2023 | benzinga.comDow Surges 250 Points; US Manufacturing PMI Tops ExpectationsOctober 24, 2023 | benzinga.comWhy InMed Pharmaceuticals Stock Is Soaring TuesdayOctober 3, 2023 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Releases FY 2023 Report, Shares Corporate UpdateSeptember 29, 2023 | finance.yahoo.comInMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business UpdateSeptember 15, 2023 | benzinga.comThis Clinical Stage BioPharma Is Seeing Solid Growth In Rare Cannabinoid Demand From The Health And Wellness SectorSeptember 7, 2023 | finance.yahoo.comInMed to Present at H.C. Wainwright 25th Annual Global Investment ConferenceJuly 22, 2023 | au.finance.yahoo.comINM - InMed Pharmaceuticals Inc.July 21, 2023 | finance.yahoo.comInMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ETJune 22, 2023 | msn.comWhy Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionJune 22, 2023 | finance.yahoo.comWhy Are InMed Pharmaceuticals Stock Trading Lower TodayJune 22, 2023 | finance.yahoo.comInMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis BullosaJune 1, 2023 | msn.comStudy Unveils Rare Cannabinoid As Promising Hope For Alzheimer's, Parkinson's & Huntington's TreatmentJune 1, 2023 | finanznachrichten.deInMed Pharmaceuticals: InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience MeetingJune 1, 2023 | finance.yahoo.comInMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience MeetingMay 24, 2023 | finance.yahoo.comInMed to Participate in Upcoming Virtual Investor EventsMay 18, 2023 | finance.yahoo.comInMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ETMay 15, 2023 | seekingalpha.comInMed Pharmaceuticals GAAP EPS of -$0.60, revenue of $1.03MSee More Headlines Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today12/03/2023Next Earnings (Estimated)2/16/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INM CUSIPN/A CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$45.00 High Stock Price Target$45.00 Low Stock Price Target$45.00 Potential Upside/Downside+9,900.0%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,950,000.00 Net Margins-147.87% Pretax Margin-147.74% Return on Equity-57.65% Return on Assets-49.23% Debt Debt-to-Equity RatioN/A Current Ratio6.19 Quick Ratio5.35 Sales & Book Value Annual Sales$4.14 million Price / Sales0.57 Cash FlowN/A Price / Cash FlowN/A Book Value$1.82 per share Price / Book0.25Miscellaneous Outstanding Shares5,260,000Free Float5,182,000Market Cap$2.37 million OptionableNot Optionable Beta-0.04 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Eric A. Adams B.S. Chem. (Age 59)M.I.B., President, CEO & Director Comp: $347.82kMr. Michael Woudenberg P.Eng. (Age 54)Chief Operating Officer Comp: $287.54kMs. Alexandra Diane-Janet Mancini M.Sc. (Age 70)Senior Vice President of Clinical & Regulatory Affairs Comp: $279.39kDr. Sazzad Hossain M.Sc. (Age 65)Ph.D., Co-Founder Comp: $133.8kMr. Jonathan R. Tegge (Age 33)Interim Chief Financial Officer Ms. Sarah Li CPACGA, VP of Accounting & ControllerColin ClancySenior Director of Investor RelationsMr. Jerry P. GriffinVice President of Sales & MarketingDr. Eric Chih-Hsien Hsu (Age 53)Senior Vice President of Preclinical Research & Development Comp: $253.46kDr. Shane A. Johnson Ph.D.Senior VP & GM of BayMedicaMore ExecutivesKey CompetitorsNovaBay PharmaceuticalsNYSE:NBYComera Life SciencesNASDAQ:CMRAJanOneNASDAQ:JANPaxMedicaNASDAQ:PXMDBellicum PharmaceuticalsNASDAQ:BLCMView All Competitors INM Stock Analysis - Frequently Asked Questions What is InMed Pharmaceuticals' stock price target for 2024? 0 Wall Street analysts have issued 12 month price targets for InMed Pharmaceuticals' stock. Their INM share price targets range from $45.00 to $45.00. On average, they expect the company's stock price to reach $45.00 in the next year. This suggests a possible upside of 9,900.0% from the stock's current price. View analysts price targets for INM or view top-rated stocks among Wall Street analysts. How have INM shares performed in 2023? InMed Pharmaceuticals' stock was trading at $2.02 on January 1st, 2023. Since then, INM stock has decreased by 77.7% and is now trading at $0.45. View the best growth stocks for 2023 here. Are investors shorting InMed Pharmaceuticals? InMed Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 4,900 shares, a decrease of 74.1% from the October 31st total of 18,900 shares. Based on an average daily volume of 1,740,000 shares, the short-interest ratio is currently 0.0 days. View InMed Pharmaceuticals' Short Interest. When is InMed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 16th 2024. View our INM earnings forecast. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($6.25) EPS for the quarter, topping analysts' consensus estimates of ($8.75) by $2.50. InMed Pharmaceuticals had a negative trailing twelve-month return on equity of 57.65% and a negative net margin of 147.87%. When did InMed Pharmaceuticals' stock split? Shares of InMed Pharmaceuticals reverse split on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:INM) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.